Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 18/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895608 | 1.00 | HDAC8 (0.56) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL3751401 | 1.00 | HDAC8 (0.56) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| Hydrochloric Acid SCHEMBL3740714 | 0.98 | HDAC8 (0.58) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| Hydrochloric Acid SCHEMBL3740720 | 0.98 | HDAC8 (0.58) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| Hydrochloric Acid SCHEMBL3751396 | 0.98 | HDAC8 (0.58) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL23387519 | 0.87 | HDAC8 (0.48) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL2491363 | 0.87 | HDAC8 (0.43) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL30036796 | 0.87 | HDAC8 (0.48) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL18480859 | 0.87 | HDAC8 (0.43) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL7633728 | 0.87 | HDAC8 (0.48) | HDAC8HDAC1HDAC3HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| US-7709484-B1 | Substituted melanocortin receptor-specific piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| CN-101061116-A | Sulfonamide compounds | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | HDAC8 3093/4885HDAC1 2884/4885HDAC3 3436/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | HDAC8 3093/4885HDAC1 2884/4885HDAC3 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.